Are stem cells and T cells best transplanted separately?

References

• Hale G, Zhang MJ, Bunjes D et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejec-
   Google Scholar
• Drobyski WR. Evolving strategies to address adverse transplant outcomes associated with T-cell depletion. 7Hematother Stem Cell Res 2000;9:327— 37.
   PubMedGoogle Scholar
• Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation plantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 1993;11:329— 36.
   Google Scholar
• Johnson BD, Becker EE, Truitt RL. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 1999;5:123— 32.
   Google Scholar
• Barrett AJ, Mavroudis D, Tisdale J et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 1998;21:543–51.
   PubMed Web of Science ®Google Scholar
• Naparstek E, Or R, Nagler A et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Cam-path-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br Haematol 1995;89:506— 15.
   PubMed Web of Science ®Google Scholar
• Elmaagacli AH, Peceny R, Steckel N et al. Outcome of transplantation of highly purified peripheral blood CD34± cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003;101:446— 53.
   PubMed Web of Science ®Google Scholar
• Ferra C, Rodriguez-Luaces M, Gallardo D et al. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001;28:963 —8.
   PubMed Web of Science ®Google Scholar
• Martino R, Martin-Henao G, Sureda A et al. Allogeneic peripheral blood stem cell transplantation with CD34± -cell selection and delayed T-cell add-back in adults. Results of a single center pilot study. Haematologica 2000;85:1165— 71.
   PubMed Web of Science ®Google Scholar
• Kobbe G, Fenk R, Neumann F et al. Transplantation of allogeneic CD34± -selected cells followed by early T-cell add-backs: favourable results in acute and chronic myeloid leukemia. Cytotherapy 2004;6:533 — 42.
   PubMed Web of Science ®Google Scholar
• Ferrara JL. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993;5:794–9.
   PubMed Web of Science ®Google Scholar
• Shlomchik WD. Antigen presentation in graft-vs-host disease. Exp Hematol 2003;31:1187–97.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850–4.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Bahceci E, Read EJ et al. Transplant dose of CD34(± ) and CD3( ) cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted per-ipheral blood stem cell transplants with delayed donor lympho-cyte add-back. Br 7 Haematol 2001;115:95–104.
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 1995;15:591 —4.
   PubMed Web of Science ®Google Scholar
• Hale G, Slavin S, Goldman JM et al. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? Bone Marrow Transplant 2002;30:797— 804.
   PubMed Web of Science ®Google Scholar
• Zikos P, Van Lint MT, Frassoni F et al. A Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low dose cyclosporine versus low-dose cyclosporine and low-dose methotrexate. Blood 1998;91:3503— 8.
   PubMed Web of Science ®Google Scholar
• Locatelli F, Zecca M, Rondelli R et al. Graft versus host diseaseprophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000;95:1572 — 9.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Nakamura R, Read EJ et al. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. Bone Marrow Transplant 2003;31:783–8.
   PubMed Web of Science ®Google Scholar
• Solomon SR, Tran T, Carter CS et al. Optimized clinical scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GVHD prophylaxis in allogeneic peripheral blood stem cell transplantation. Cytotberapy 2002;4:395 — 406.
   PubMed Web of Science ®Google Scholar
• Chen BJ, Cui X, Liu C, Chao NJ. Prevention of graft-versus-hostdisease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 2002;99:3083–8.
   PubMed Web of Science ®Google Scholar
• Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002;360:130— 7.
   PubMed Web of Science ®Google Scholar